Abstract
MIDD0301 is a novel new chemical entity (NCE) drug that targets GABAA receptors in the lung. This unique mechanism of drug action for asthma avoids common therapeutic targets, such as glucocorticoid and β-adrenergic receptors that are subject to tolerance and adverse effects. MIDD0301 is expected to have broader clinical utility compared to current inhaled and oral treatments due to alleviation of Th1 and Th2 mediated lung inflammation, in addition to the relief of airway hyperresponsiveness (AHR).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
